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Abstract
Cell-mediated immunity plays a key role in host control of viral infection. This is exemplified
by life-threatening reactivations of e.g. herpesviruses in individuals with impaired T-cell and/
or iNKT cell responses. To allow lifelong persistence and virus production in the face of
primed immunity, herpesviruses exploit immune evasion strategies. These include a reduc-
tion in viral antigen expression during latency and a number of escape mechanisms that tar-
get antigen presentation pathways. Given the plethora of foreign antigens expressed in
virus-producing cells, herpesviruses are conceivably most vulnerable to elimination by cell-
mediated immunity during the replicative phase of infection. Here, we show that a prototypic
herpesvirus, Epstein-Barr virus (EBV), encodes a novel, broadly acting immunoevasin,
gp150, that is expressed during the late phase of viral replication. In particular, EBV gp150
inhibits antigen presentation by HLA class I, HLA class II, and the non-classical, lipid-pre-
senting CD1d molecules. The mechanism of gp150-mediated T-cell escape does not
depend on degradation of the antigen-presenting molecules nor does it require gp150’s
cytoplasmic tail. Through its abundant glycosylation, gp150 creates a shield that impedes
surface presentation of antigen. This is an unprecedented immune evasion mechanism for
herpesviruses. In view of its likely broader target range, gp150 could additionally have an
impact beyond escape of T cell activation. Importantly, B cells infected with a gp150-null
mutant EBV displayed rescued levels of surface antigen presentation by HLA class I, HLA
class II, and CD1d, supporting an important role for iNKT cells next to classical T cells in
fighting EBV infection. At the same time, our results indicate that EBV gp150 prolongs the
timespan for producing viral offspring at the most vulnerable stage of the viral life cycle.
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Author Summary
The human herpesvirus Epstein-Barr virus (EBV) is an important human pathogen
involved in infectious mononucleosis and several malignant tumors, including lymphomas
in the immunosuppressed. Upon primary infection, a balance between virus and host is
established, to which EBV’s capacity to dodge T cell-mediated attack contributes. Here we
identify the late protein EBV gp150 as a novel immunoevasin, frustrating antigen presen-
tation by HLA class I, class II, and CD1d molecules. EBV gp150’s many sialoglycans create
a shield impeding surface detection of presented antigen. Interestingly, exploiting glycan
shielding as a mechanism to mask surface exposed proteins on infected cells could permit
EBV to additionally modulate other aspects of host antiviral defense. B cells producing
wild-type EBV escaped immune recognition more efficiently than those infected with a
gp150-null virus, pointing towards a role for gp150 in natural infection. Our results reveal
a novel, broadly active strategy by which a herpesvirus glycoprotein, EBV gp150, blocks
antigen presentation to T cells through glycan shielding, a new paradigm in herpesvirus
immune evasion.
Introduction
Viruses are exceptionally well equipped to adjust processes in infected host cells to support
their own replication and survival. Especially in persistent infections, they must withstand
many layers of anti-viral activities exerted by the host immune system. Cell-mediated immu-
nity, in particular that mediated by antigen (Ag)-specific T cells, is essential for elimination of
virus-infected cells, reducing viral replication, and stimulating other immune effector
functions.
CD8+ and CD4+ T cells are activated by peptide Ags presented at the cell surface in the con-
text of HLA class I and class II (HLA I and II) molecules, respectively. In contrast, invariant
natural killer T (iNKT) cells, a subset of specialized T cells characterized by a semi-invariant T
cell receptor (TCR) in combination with NK cell receptors, recognize lipid Ags presented by
CD1d, a non-classical, non-polymorphic HLA molecule. Upon activation, iNKT cells secrete a
vast array of polarizing cytokines and they can also directly exert cytotoxicity [1]. In addition
to the anti-viral cytotoxic and helper T cells, a role for iNKT cells in providing protection
against viral infection has more recently been appreciated [2].
Herpesviruses are widespread viruses that establish lifelong persistent infections in their
host, even in the face of virus-specific immunity [3]. Within their large (125–230 kb) DNA
genomes, herpesviruses encode functions essential for viral replication, yet many additional
gene products are non-essential for propagation in vitro. Evidence is accumulating that the lat-
ter are required for establishment of the delicate balance between viral replication and host
responses in vivo. Among these gene products are immune evasion molecules that frustrate the
activation of cell-mediated immunity by thwarting Ag presentation. The fact that such gene
products have been independently acquired and maintained by multiple members of the her-
pesvirus family throughout millions of years of coevolution with their host testifies to the
importance of T cell activation in the control of herpesvirus infection [4].
In humans, the in vivo contribution of cell-mediated immunity to fighting viral infection is
probably best demonstrated for Epstein-Barr virus (EBV). This γ-herpesvirus was the first
human tumor virus discovered [5], being associated with malignancies such as Burkitt’s lym-
phoma and nasopharyngeal carcinoma. EBV is carried by more than 90% of adults worldwide,
mostly asymptomatically. When primary EBV infection occurs during adolescence or
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adulthood, it presents in more than 50% of cases as self-limiting infectious mononucleosis [6],
in which viral replication is eventually controlled by the EBV-specific immune response. This
contrasts to patients with the primary immunodeficiency X-linked lymphoproliferative syn-
drome (XLP) who develop an often fatal mononucleosis when infected by EBV [6]. XLP
patients have a genetic defect leading to nonfunctional T and NK cells and the absence of
iNKT cells [7,8]. In addition, EBV can cause life-threatening lymphomas when cell-mediated
immunity is insufficient, for instance in transplantation or AIDS patients. Reconstitution of
EBV-specific T cell immunity by adoptive transfer provides a cure for post-transplantation
lymphoproliferative disease (PTLD) [9]. PTLD and XLP thus occur in two distinct patient
groups having in common that they lack sufficient cell-mediated immunity to control EBV
infection.
Like other herpesviruses, EBV has acquired ingenious strategies to escape elimination by
cell-mediated immunity of the immunocompetent infected host. Among these, EBV downre-
gulates its Ag expression in the latent stage of infection and exploits (viral) immune evasion
gene products, in particular during its replicative phase, to interfere with immune activation
[10]. In the early lytic phase, Ag presentation by HLA I is reduced by the concerted action of
(at least) three EBV proteins: BNLF2a blocks antigenic peptide supply [11], BILF1 diverts HLA
I complexes away from the cell surface [12], and the shutoff protein BGLF5 acts as an RNase
that arrests synthesis of, for instance, HLA I, II, and CD1d [10]. Silencing expression of these
early EBV proteins in B cells supporting productive infection yielded only partially rescued sur-
face display of the Ag-presenting molecules [13,14]. This led to the hypothesis that EBV
encodes additional immune evasion molecules targeting CD1d, HLA I, and HLA II, but their
identity has remained elusive. In this study, we took a global look at Ag presentation by EBV-
producing B cells with a focus on the late phase of infection, when most Ags are expressed that
could activate T and iNKT cell immunity.
We identified the heavily glycosylated EBV protein gp150, encoded by the BDLF3 gene, as a
new viral immune evasion molecule. BDLF3 is unique to EBV and the closely related Rhesus
lymphocryptovirus (LCV). EBV gp150 interferes with immune recognition of HLA I, II, and
CD1d/ Ag complexes at the cell surface. We provide evidence that gp150 shields the recogni-
tion of these surface molecules in a glycan-dependent manner. This represents a novel immune
evasion mechanism in herpesviruses.
Results
Identification of EBV BDLF3-encoded gp150 as a novel immune evasion
molecule
To study alterations in surface display of Ag-presenting molecules in the course of productive
EBV infection of B cells, we employed our previously described EBV+ AKBM Burkitt’s lym-
phoma (BL) system [15]. Following anti-human IgG treatment, cells supporting replication of
EBV are identified in flow cytometry by expression of a lytic cycle reporter, rat CD2-GFP, and/
or EBV lytic proteins, such as the gHgL complex (Fig 1A, upper row). Surface display of the
Ag-presenting molecules HLA I, II, and the non-classical HLA molecule CD1d is markedly
reduced on EBV-producing cells in comparison to latently infected control cells (Fig 1A, left
panels), in line with our earlier reports [13,15]. Downregulation of surface HLA I complexes
commenced around 8–10 hours post induction of the lytic cycle [15], preceding that of HLA II
and CD1d. Surface levels of the latter were progressively reduced on EBV-producing cells with
a delay of about 4–6 hours compared to HLA I (S1A Fig and [15]). To distinguish the contribu-
tions of late versus (immediate-)early EBV proteins to the downregulation of surface Ag-pre-
senting molecules, phosphonoacetic acid (PAA) was used to arrest viral replication at the early
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phase. Upon anti-human IgG treatment of AKBM cells in the presence of PAA, late EBV pro-
tein expression of, for instance, gHgL complexes was inhibited, while the early rat CD2GFP
reporter was still expressed (Fig 1A, upper row). At the surface of PAA-treated cells, CD1d and
HLA II levels were mostly retained (Fig 1A, right panels), pointing towards involvement of late
EBV protein(s) in T and iNKT cell immune evasion. HLA I downregulation was partly rescued
upon PAA treatment indicating that, next to the early EBV proteins previously identified, also
viral late proteins play a role in reducing the surface levels of HLA I (Fig 1A, right panels). In
conclusion, one or several of the 30 late EBV proteins interfere with surface display of the
CD1d, HLA I, and HLA II Ag-presenting molecules.
To identify the late EBV gene product(s) responsible for interference with Ag presentation
observed during productive infection, we took the approach of expressing individual, or combi-
nations of late viral genes in 293T-CD1d cells through plasmid transfection (Fig 1B and 1C)
and/or in MJS-CD1d cells via lentiviral transduction (Figs 1D and S1). Screening of late EBV
genes in 293T-CD1d cells revealed that most glycoproteins did not affect surface levels of
CD1d (Fig 1B), HLA I, or the control protein transferrin receptor (TfR) to a major extent (S1B
Fig). Also expression of EBV gB did not target CD1d, even though its homologue in herpes
simplex virus type 1 (HSV-1) was found to act in concert with the viral kinase US3 to mediate
intracellular retention of CD1d molecules observed during HSV-1 infection [16]. EBV gp350
caused some downregulation of CD1d, yet the strongest effect was observed for gp150, encoded
by the BDLF3 gene (Fig 1B). Expression of EBV gp150 at levels comparable to those observed
in virus-producing B cells (Fig 1C, left panels) resulted in marked downregulation of both Ag-
presenting molecules tested (upper panels), which was not evident in control transfected cells.
The dot plots show an apparent threshold to gp150 levels resulting in loss of HLA I and CD1d
detection. These combined data demonstrate that expression of the BDLF3-encoded EBV
gp150 reduces the detection of HLA I and CD1d at the cell surface.
Finally, we determined whether the timing of gp150 expression during productive EBV
infection of human B cells would match the observed downregulation of Ag-presenting mole-
cules. To visualize total gp150 protein levels in the course of EBV reactivation in B cells, we
used an antibody (Ab) directed against its intracellular cytoplasmic tail [19]. Whereas the early
EBV protein BGLF5 was detectable from 4 hours post induction [15] onwards, no gp150 pro-
tein was found before 8–10 hours into lytic infection with clear detection from 12 hours
onwards (Fig 1D), leaving enough time to influence HLA I, II, and CD1d expression at late
times. These combined data point to gp150 interfering with surface detection of Ag-presenting
molecules on EBV-producing B cells. Since no function had hitherto been ascribed to the EBV
glycoprotein gp150, its role in immune evasion of Ag-presenting molecules was further
investigated.
Fig 1. gp150 interferes with surface display of Ag-presenting molecules during productive EBV infection. A) EBV+ AKBM-CD1d BL cells were treated
for 20 hours with anti-human IgG Ab to induce viral replication. EBV-producing cells were identified by induced expression of the lytic cycle reporter rat
CD2-GFP. In the presence of PAA, productive infection is arrested before late protein expression. Surface levels of the EBV late complex gHgL and of the
Ag-presenting molecules HLA I, II, and CD1d were determined by flow cytometry. Histograms depict overlays to allow comparison of latently (GFP-) and
lytically (GFP+) infected B cells. B) 293T-CD1d cells were transfected with expression vectors encoding late EBV glycoproteins. Glycoproteins known to
require a viral interaction partner were transfected together (BMRF2/BDLF2 and gM/gN). EBV protein expression was deduced from coexpression of GFP
(BMRF2/BDLF2) or on the basis of a C-terminal tag (gM/gN, gB, gp350, gp150). Cell surface CD1d was stained prior to an intracellular staining for the tagged
EBV proteins. Surface levels were compared between non-transfected and transfected cells. C) 293T-CD1d cells were transfected with N-terminally HA-
tagged gp150 or an empty IRES-GFP vector control. Total gp150 expression was determined by intracellular staining and was compared to levels in EBV-
producing B cells. The other histograms depict surface levels of HA (HA-gp150), HLA I, and CD1d staining for empty vector-transfected and gp150+GFPhigh
293T-CD1d cells; GFPhigh gating as indicated in the dot plots. D) Expression of gp150 was assessed at different time points during productive EBV infection
of B cells; the early EBV antigen BGLF5 was taken along as a control (time points 6–10 hours and 12–20 hours are from different experiments).
doi:10.1371/journal.ppat.1005550.g001
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EBV gp150 causes expression level-dependent interference with
different cell surface molecules
To study gp150’s phenotype and mechanism of action in more detail, we expressed the EBV
protein in MJS-CD1d cells via lentiviral transduction, together with GFP as a marker for suc-
cessful transduction. This approach was validated with known EBV evasion molecules
[11,17,18] that specifically reduced surface display of HLA I (BNLF2a and BILF1) or HLA II
(gp42gHgL). At the same time, this experiment showed that the known EBV T cell immunoe-
vasins did not interfere with CD1d expression (S2A Fig).
HLA I and CD1d downregulation from the GFP+ MJS-CD1d-gp150 cells (Figs 2A and S2B)
indicated that this immune evasive phenotype was not limited to transient overexpression in
Fig 2. EBV gp150 is broadly acting, but displays a degree of specificity for antigen-presenting molecules. Flow cytometric analyses of MJS-CD1d
cells (adherent fraction) three days post transduction with gp150-IRES-GFP lentiviruses. A) Total EBV gp150 levels were determined by intracellular staining
of permeabilized cells. Surface levels of HLA I, II, CD1d, CD10, and CD54 were determined using Ab staining on non-permeabilized cells. B) Surface levels
of CD1d and CD54 are depicted as log MFI values with 95% confidence intervals, for GFP+ versus GFP- MJS-CD1d cells transduced with gp150 or a GFP
control. The slopes of the connecting lines reflect the declines in fluorescence (Δlog MFI) and, thus, the downregulation of HLA I, II, CD1d, CD10, and CD54
induced by gp150 (for the GFP control, the Δlog MFI did not significantly differ from 0). C) Cell surface levels of HLA I, II, CD10, CD34, CD44, and CD54 were
determined using surface Ab staining. EBV gp150-induced downregulation of these molecules was calculated as in B) and represented as Δlog MFI.
doi:10.1371/journal.ppat.1005550.g002
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293T cells (Fig 1). Furthermore, gp150 downregulated surface levels of HLA II and also affected
other molecules such as CD10, CD54 (Fig 2A), and TfR (S2B Fig). To allow easier comparison of
gp150’s effects on various cell surface markers, we calculated the difference in logarithmically
transformed mean fluorescence intensities (Δlog MFI) for each surface marker to serve as a mea-
sure for the extent of gp150-mediated downregulation, by subtracting the logMFI values for cells
that were non- (GFP-) or successfully (GFP+) transduced with either gp150-IRES-GFP or a con-
trol GFP lentivirus (Fig 2B right panel; the left panels show examples of the log MFI for CD1d
and CD54). This approach visualized that the antigen-presenting molecules HLA I, II and CD1d
were more sensitive to EBV gp150 downregulation than the CD10 and CD54 molecules (Fig 2B).
To investigate if gp150’s effects reflect level-dependency, we transduced MJS-CD1d cells
with a range of lentivirus amounts to achieve decreasing levels of gp150 expression. This
resulted in a concomitant reduction in surface downregulation of the cellular proteins tested
(S2C Fig). When using the higher dose of gp150 lentiviruses in the adherent MJS-CD1d cells,
we observed that a proportion of cells detached from the culture dish by 3 days after transduc-
tion. This detachment did not only occur as a consequence of lentiviral transduction or of
gross gp150-induced cytotoxicity (see S3A Fig). Loss of attachment of the gp150high GFPhigh
cells coincided with a further reduced surface detection of HLA I, II, and CD1d (compare Figs
2A and S3B). Very high levels of gp150 even downregulated the cell surface molecules CD10
and CD54, which were only marginally affected in the adherent cell fraction (Figs 2A and S3B).
These results—together with the apparent threshold for gp150-induced downregulation (dot
plots in Figs 1C and 2A) and the dose-dependent effect of gp150 expression (S2C Fig)—dem-
onstrate that higher levels of gp150 cause a stronger phenotype.
Thus, EBV gp150 acts in an expression level-dependent manner to downregulate multiple
cell surface molecules, to different extents.
Finally, to obtain an impression of the target range of gp150, we looked for surface mole-
cules on MJS-CD1d cells that were not downregulated by the EBV protein. We found that vir-
tually equal levels of CD34, CD44, and CD55 were detected on cells that did or did not express
gp150, even when gated on the GFPhigh fractions of cells (Fig 2C). From these data we conclude
that various cell surface molecules display differential sensitivity to EBV gp150, with CD34,
CD44, and CD55 as examples of proteins that are resistant (Fig 2). Since gp150 has a strong
effect on the Ag-presenting molecules HLA I, II, and CD1d, this EBV glycoprotein appears to
be a broadly acting immune evasion molecule.
EBV gp150-induced downregulation of Ag-presenting molecules impairs
T cell activation
Next, we intended to determine the functional consequences of EBV gp150-induced immune
evasion. Reduced surface HLA I, II, and CD1d levels were detected with Abs that are capable of
blocking many TCR–HLA/Ag interactions (Figs 1 and 2), pointing towards functional rele-
vance of gp150’s blocking activity.
To assess if EBV gp150 expression in Ag-presenting cells affects T cells activation, the
capacity of HLA-A2+DR3+ MJS-A2 cells to induce interferon (IFN)-γ production was moni-
tored with well-defined T cell clones with different specificities. Activation of CD8+ T cells spe-
cific for a human cytomegalovirus (HCMV) pp65 epitope presented in the context of HLA-A2
was analysed after stimulation with pp65-expressing MJS-A2 cells that did or did not co-
express EBV gp150 (Fig 3A). Whereas GFP+ control cells efficiently activated the T cells, IFN-γ
production was markedly reduced in T cells cultured with gp150-expressing Ag-presenting
cells (Fig 3A). The use of another T cell clone, a CD4+ T cell directed against a minor histocom-
patibility Ag (MiHa) endogenously expressed by MJS cells and presented in the context of
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HLA-DR3, allowed us to study inhibition of T cell responses restricted by HLA II. Diminished
secretion of IFN-γ by the T-helper cells was observed in response to cells expressing gp150
compared to control cells (Fig 3B). These results show that not only detection of Ag-presenting
molecules by Ab was blocked by gp150, but also T cell activation was hampered.
T cell activation upon target cell engagement involves formation of multiple receptor-ligand
pairs, including TCR–HLA/Ag as well as costimulatory and adhesion molecule interactions. In
view of the broader target range of EBV gp150, it could diminish multiple of these interactions.
Here, we zoomed in on the effect of gp150 onMHC/peptide–TCR interactions. To this end,
human 293T cells were used that express the mouse MHCmolecule H-2Kb to present the ovalbu-
min-derived SIINFEKL epitope. Display of SIINFEKL-loaded Kb molecules at the cell surface
was detected with the 25D1.16 Ab, thereby recapitulating TCR binding (Fig 3C). Upon introduc-
tion of EBV gp150 into these cells, a significant reduction in surface levels of epitope-loaded Kb
molecules was observed (Fig 3C and 3D). This further supports the conclusion that T cell activa-
tion is diminished upon gp150-induced downregulation of surface Ag-presenting complexes.
Fig 3. Cellular expression of EBV gp150 limits CD8+ and CD4+ T cell activation by disrupting Ag
presentation. A,B) MJS-A2-pp65 cells were lentivirally transduced to express gp150 or control GFP (vector).
Ag-presenting cells expressing low or high levels of gp150 protein were obtained by harvesting the floating
cells and by FACS-sorting the adherent GFP+ fraction into GFPint and GFPhigh cells. Following overnight co-
culture of these cells with either A2/pp65-specific CD8+ (A) or DR3/MiHa-specific CD4+ T cells (B), IFN-γ
secretion into the culture supernatants was determined by ELISA. Relative T cell recognition is depicted with
IFN-γ levels produced in response to stimulation with vector control cells set at 100%. C) 293T-Kb cells were
transfected with an empty vector control or gp150. Cells were pulsed with SIINFEKL or a control peptide
(SSIEFARL) and stained with Ab 25D1.16, which is specific for Kb/ SIINFEKL complexes. D) Statistical
analysis of three independent experiments (performed as in C)) using the Student’s t-test (two-tailed).
doi:10.1371/journal.ppat.1005550.g003
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Our combined results indicate that EBV gp150 impairs Ag presentation to both HLA I- and
II-restricted T cells.
EBV gp150 does not induce the degradation of Ag-presenting molecules
Having demonstrated the functional impact of gp150-induced T cell evasion, we wanted to
unravel its mechanism of action. In the remainder of these studies, we focused on the adherent
fraction of gp150-expressing cells, although the effects might even be stronger for floating cells.
In addition, we made use of constructs that encode gp150 with an N-terminal HA-tag (Fig 4A)
to allow visualisation of the proportion of this EBV molecule expressed at the cell surface.
First, we investigated if reduced surface display of Ag-presenting molecules was due to
gp150-induced protein degradation. Degradation of HLAmolecules either by proteasomes resid-
ing in the cytoplasm or by endolysosomal proteases is an evasion strategy exploited by a number
of herpesviruses, for instance by HCMV and by Kaposi’s sarcoma herpesvirus [4]. For EBV
gp150-induced effects, however, no difference in surface levels was observed for HLA I or CD1d
in the presence either of the proteasome inhibitor epoxomicin or of chloroquine, an inhibitor of
the endolysosomal degradation pathway (Fig 4B). Of note, HA-gp150 molecules arrived at the cell
surface, irrespective of treatment with these inhibitors. Additionally, intracellular staining with the
D5 Ab, which detects free CD1d heavy chains (not associated with β2m) [20], revealed no reduc-
tion in this intracellular population of CD1d molecules in the presence of gp150 (Fig 4B, right
panels), suggesting that gp150 does not induce degradation of newly synthesized CD1d molecules.
In an alternative approach, we compared gp150’s effect on surface display directly to that on
total cellular levels of HLA I in the form of an N-terminally eGFP-myc-tagged HLA-A2 mole-
cule [21], which was introduced into the HLA-A2- cell line MJS (MJS-GFPmycA2 cells). In the
non-permeabilized cells, GFP fluorescence reflected total levels of this fusion protein and, at
the same time, surface levels were visualized with Abs directed to the extracellular myc-tag or
HLA-A2 epitope (BB7.2). High levels of BB7.2 and anti-myc Ab staining as well as GFP fluo-
rescence were detected in MJS-GFPmycA2 cells by flow cytometry (Fig 4C, non-transduced
cells), indicating that the HLA-A2 fusion protein was properly expressed and reached the cell
surface. Upon subsequent introduction of HA-gp150, we observed a strong reduction in sur-
face detection of the chimeric HLA-A2 molecule, whereas total GFP levels remained unaffected
(Fig 4C, gp150+ cells). These data implicate that in gp150-expressing cells total levels of HLA
molecules remain unaltered, yet their surface detection is reduced.
In the same experimental set-up, we studied which part(s) of gp150 are essential for
immune evasion. EBV gp150 is a type I membrane protein with a short cytoplasmic tail (Fig
4A). Some herpesvirus proteins, such as EBV BILF1, depend on their cytoplasmic tail for inter-
ference with Ag presentation [22]. As deletion of 26 amino acids from the C-terminus of gp150
(HA-gp150ΔC) did not impair the apparent downregulation of HLA I (endogenous and
A2-GFP; Fig 4C, lower panels) or of CD1d from the cell surface, we conclude that the immune
evasion function of gp150 is independent of its cytoplasmic tail.
The combined data obtained upon protease inhibitor treatment and with the GFPmycA2
fusion protein demonstrate that gp150 does not promote degradation of Ag-presenting mole-
cules as an immune evasive strategy.
EBV gp150 prevents detection of Ag-presenting molecules at the cell
surface
Although the Ag-presenting molecules were not degraded in gp150+ cells, they were not detect-
able at the cell surface either. Therefore, we probed the intracellular location of these molecules
both in gp150-expressing cells and controls.
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Fig 4. Immune evasion by EBV gp150 does not depend on degradation of Ag-presenting molecules nor on gp150’s cytoplasmic tail. A) Schematic
overview of the gp150 constructs and Abs used. Signal peptide, transmembrane domain, and cytoplasmic tail are abbreviated as signal pept, TM, and cytopl
tail, respectively. B) Three days after lentiviral transduction, MJS-CD1d-gp150 cells were cultured overnight in the presence of an inhibitor of proteasomes
(15nM epoxomicin) or of endolysosomal proteolysis (25μM chloroquine). Subsequently, flow cytometry was used to determine surface levels of HA-tagged
gp150 (HA-gp150; detected with anti-HA Ab), HLA I, and mature CD1d (Ab #42) complexes on non-permeabilized cells and intracellular staining was
performed to detect immature CD1d (Ab D5) molecules in permeabilized cells. C) MJS-GFPmycA2 cells were transduced with a lentivirus encoding HA-
gp150 (upper) or HA-gp150ΔC (lower). Cell surface levels of CD1d, HLA I, and HLA-A2 (BB7.2 and anti-myc tag) and total HLA-A2 (GFP) levels were
compared for gp150- and gp150+ cells.
doi:10.1371/journal.ppat.1005550.g004
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As trafficking of newly synthesized glycoproteins from the ER onwards is reflected by the
progressive maturation of their glycans, we compared the migration of the CD1d and HLA I
heavy chains in Western blots using lysates of sorted populations of control and gp150-trans-
duced cells (non-transduced, vector, and gp150low/high, respectively; see S4 Fig). Differentially
glycosylated maturation forms of these Ag-presenting molecules were identified upon glycosi-
dase treatment. Endoglycosidase H (Endo H) removes high-mannose N-linked glycans, but
not complex glycans that arise after the transport of glycoproteins beyond the cis-Golgi com-
partment. Peptide N-glycosidase F (PNGase F) treatment reveals the deglycosylated protein
backbone, as it removes all N-linked glycans regardless of their maturation. Mature CD1d
heavy chains carry 4 N-linked glycans, three of which become Endo H-resistant and one of
which remains Endo H-sensitive [23]. In untreated control cells, two CD1d bands were
detected that probably reflect different glycosylation stages of CD1d (Fig 5A,+CHO, lanes 1
and 4). PNGase F treatment resulted in one dominant band and a very faint band, reflecting
virtually complete deglycosylation of CD1d heavy chains (-CHO, lanes 3 and 6). Endo H treat-
ment revealed the deglycosylated CD1d heavy chain (-CHO, lanes 2 and 5); the two additional
bands represent Endo H-resistant heavy chains, showing that these CD1d molecules have trav-
elled beyond the cis-Golgi.
The HLA I heavy chain carries a single N-linked glycan and only one band is observed in
untreated control cell lysates (lanes 1 and 3), which is removed upon digestion with both
PNGase F (lanes 3 and 6) and Endo H (lanes 2 and 5). Only a minor fraction of the HLA I mol-
ecules apparently becomes Endo H-resistant in these MJS cells.
The pattern of maturation forms of CD1d and HLA I in gp150+ cells was virtually identical
to that observed in control cells (compare lanes 1–6 to 7–12). If anything, the mature, Endo H-
resistant heavy chains were more prominent in gp150+ cells. From these data, we conclude that
the ER-to-Golgi trafficking of new HLA I and CD1d molecules is not inhibited in the presence
of EBV gp150. Furthermore, the presence of the heavily glycosylated viral protein in the ER
does not appear to act as a “glycosylation sink” preventing the exit of newly synthesized Ag-
presenting molecules.
Confocal microscopy allows the visualisation of Ag-presenting molecules within the cell as
well as their potential colocalization with EBV gp150 [22]. For these experiments, we employed
non-permeabilized, non-fixed MJS cells expressing a C-terminal GFP fusion molecule of
HLA-A2 (A2GFP), which had been used before in microscopy studies on HLA I maturation
and trafficking [24]. Flow cytometry analysis confirmed that this HLA-A2 fusion protein
behaved similarly to the other Ag-presenting molecules tested. Introduction of gp150 in
MJS-A2GFP cells decreased surface detection by HLA I-specific Abs, while GFP fluorescence
indicated that the total amount of cellular A2GFP molecules was not altered by gp150 (Fig 5B).
In confocal microscopy, gp150+ MJS-A2-GFP cells were identified based on positive staining
for the HA-tag attached to gp150 (in red; Fig 5C, lower left panel), which confirmed that HA-
gp150 molecules arrived at the cell surface. Focusing on the non-transduced (HA-) control
cells, the GFP signal shows localization of A2GFP fusion proteins at the plasma membrane (Fig
5C, upper right panel). Accordingly, the surface-exposed A2GFP molecules were detectable
with Ab BB7.2 (Fig 5C, upper left panel), yet only in the non-transduced fraction of cells. This
costaining demonstrated the integrity of the chimeric HLA-A2 molecule. Using Ab-staining
(BB7.2), surface A2GFP molecules were not detected on the gp150+ fraction of cells by confocal
microscopy (Fig 5C, upper left panel), as may have been anticipated from the flow cytometry
data described above (Figs 1, 2 and 4). However, GFP fluorescence revealed the presence of the
A2GFP molecules also at the surface of gp150+ cells, where they colocalized with gp150 (Fig
5C, right panels). The arrival of HLA I molecules at the surface of both gp150+ and control
cells, indicates that gp150 does not alter the localization of these Ag-presenting molecules.
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Quantification of multiple microscopy pictures supports that the Ab-based detection of
HLA-A2-GFP is significantly reduced for gp150-expressing cells compared to control cells and
this was not due to reduced GFP fluorescence intensity at the cell surface (Fig 5D).
Fig 5. Immune evasion by EBV gp150 occurs at the cell surface. A) The glycosylation status of CD1d and HLA I molecules in lysates of MJS-CD1d-
gp150 and control cells was analysed byWestern blot. To this end, denatured post-nuclear lysates of different FACS sorted cell populations (see S4 Fig)
were treated with Endo H or PNGase F to remove N-linked glycans. Endo H digestions served to examine protein transport beyond the cis-Golgi
compartment; PNGase F digestions revealed the deglycosylated protein backbone (minus carbohydrates, -CHO). Actin was a loading control. B) Using the
same experimental setup as in Fig 4C, MJS-A2-GFP cells were transduced with a lentivirus encoding HA-gp150ΔC. Cell surface levels of CD1d, HLA I, and
HLA-A2 (BB7.2) and total levels of HLA-A2 (GFP) were compared for (non-permeabilized) gp150- and gp150+ cells. C) Confocal microscopy of non-
permeabilized MJS-A2GFP-HA-gp150ΔC cells. Cell surface stains were performed for HLA-A2 (BB7.2) and gp150ΔC (HA). D) Quantification of surface
expression of the indicated molecules based on multiple microscopy pictures.
doi:10.1371/journal.ppat.1005550.g005
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Together, these data indicate that cellular expression of EBV gp150 does not alter the total
protein levels or localization of HLA molecules, but prevents their Ab-based detection on the
cell surface.
EBV gp150 shields surface molecules via sialoglycans on its
ectodomain
Since the cytoplasmic tail of gp150 is not essential for immune modulation, it is likely that the
extracellular domain of gp150 is mechanistically involved. The most peculiar characteristic of
EBV gp150 is its highly abundant glycosylation, with about half of the amino acid residues in
the N-terminal domain being potential substrates for N- or O-linked glycosylation (Fig 4A). Its
extensive glycosylation is reflected by the observation that in SDS-PAGE gels, gp150 migrates
as a diffuse band with a molecular weight of 100–150 kDa, whereas the unglycosylated protein
backbone is around 30 kDa [25,26]. Although the exact glycan composition is not known,
gp150 carries many negatively-charged sialic acid moieties [25,26]. To directly assess whether
the glycan decoration on gp150 plays a role in the shielding of surface Ag-presenting mole-
cules, flow cytometry analysis was performed on gp150 expressing cells from which sialic acids
had been depleted using three different approaches.
First, we introduced human CD1d, HLA-A2, and β2m both into Lec2 cells, which are Chi-
nese hamster ovary (CHO) cells with a mutated CMP-sialic acid Golgi transporter resulting in
decreased sialylation of glycans [27], and into control CHO cells. Defective sialylation in the
Lec2 cells was confirmed by decreased binding of wheat germ agglutinin (WGA), a lectin that
binds sialic acid and N-acetylglucosamine structures (chitobiose) (Fig 6A). The effect of defec-
tive glycosylation on EBV gp150 expressed in Lec2 cells was visible by Western blot: compared
to lysates from control CHO cells, gp150 from Lec2 cell lysates migrated at a higher apparent
molecular weight, likely due to the absence of negatively charged sialic acids (Fig 6B). Staining
for surface HLA I and CD1d on Lec2 cells was somewhat increased compared to parental CHO
cells, probably reflecting a better accessibility of the Ab binding sites when the Ag-presenting
molecules are less sialylated (Fig 6C and 6D). In the CHO cells, expression of EBV gp150
decreased HLA I and CD1d staining, which was partly reversed in Lec2 cells. This indicates
that sialic acids contribute to the phenotype caused by gp150 (Fig 6C and 6D).
Second, to address the role of sialylation in protein downmodulation in human cells and,
thereby, also to be able to test a broader panel of surface markers, sialylation was inhibited by pre-
treating MJS-CD1d cells with the fluorinated sialic acid analogue P-3Fax-Neu5Ac [28]. This ana-
logue blocks sialyltransferases, enzymes that transfer sialic acids onto glycans. Inhibition of
sialylation was detected by the reduced binding of the sialic acid-binding lectins SNAI andMALII
to treated cells (Fig 6E). Strongly enhanced binding of PNA, a lectin that binds to glycan struc-
tures that become accessible upon desialylation, further confirmed successful inhibition of sialyl-
transferases following cell culture in the presence of this competitive inhibitor (Fig 6E). Similar to
the sialylation-defective hamster cells, sialyltransferase inhibitor treatment of MJS-CD1d cells
expressing gp150 was sufficient to cause the viral protein to migrate differently in SDS-PAGE (Fig
6F). Cells transduced to express gp150 that were pre-incubated with P-3Fax-Neu5Ac showed
increased surface staining for HLA I, II, and CD1d compared to control cells (Fig 6G and 6H),
consistent with a crucial role for sialylation in the shielding of Ab binding sites by gp150.
Third, to selectively cleave off cell surface sialic acids, we treated cells with neuraminidase.
Enzymatic desialylation occurred in a dose-dependent fashion, as witnessed by progressive loss
of WGA lectin binding at the cell surface (Figs 6I and S5). Selectivity of this neuraminidase
treatment for surface-exposed glycans was supported by Western blot analysis, in which a pro-
portion of gp150 molecules from treated cells displayed reduced mobility, whereas the
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remaining, likely intracellular, EBV proteins had an apparent molecular weight comparable to
that in untreated cells (Fig 6J). At the surface of gp150-transduced MJS-CD1d cells, CD1d
detection improved with increasing doses of neuraminidase (Figs 6K and S5), pointing to a
direct involvement of sialic acid-modified glycans in interference with CD1d detection. Like-
wise, surface display of the host cell molecules HLA I and HLA II was improved by neuramini-
dase treatment (Fig 6K and 6L) to the same range as observed for the inhibitor treatment (Fig
6G and 6H), suggesting that primarily sialic acids at the cell surface played a role.
In the three settings above (Fig 6), a rescue of 15–25% in the surface detection of Ag-pre-
senting molecules was observed in the presence of desialylated versus fully sialylated gp150.
This rescue being modest is perhaps due to the remaining glycan structures on gp150. Still, a
highly significant increase in display was detected in all abovementioned experimental
approaches. Therefore, these combined results provide evidence that surface sialic acid-carry-
ing N- and O-linked glycans contribute to EBV gp150’s ability to hide certain host cell surface
molecules, including those involved in Ag presentation, thereby providing a mechanistic basis
for T and iNKT cell evasion.
EBV gp150 mediates glycan shielding of Ag-presenting molecules on
human B cells
Natural EBV infection in vivo targets human B cells and epithelial cells and the main reservoir
of persistent infection is the memory B cell. To produce new offspring, EBV reactivates from
latently infected B cells carrying the viral genome. Whereas the 293T and MJS cells could
reflect epithelial infection, we specifically addressed the question if gp150-mediated immune
evasion was also operative in human B cells.
As relevant human B cells for this study, we chose Akata BL cells in latency, which upon
induction are capable of supporting productive EBV infection, implying that all host cell fac-
tors essential for EBV replication are present. These Akata BL cells are the parental equivalent
of the AKBM cells described above (without the rat CD2GFP lytic cycle reporter). In the Akata
BL background, Borza and Hutt-Fletcher [19] had previously generated a knockout mutant
EBV that lacks the BDLF3 open-reading frame coding for gp150 (AkataΔgp150 cells, see
below). For immune evasion studies, we introduced a constitutively expressed EBV gp150 gene
into these latent AkataΔgp150 B cells, thereby avoiding potential interference by any endoge-
nous gp150 expression (referred to as Akata+gp150 cells).
To achieve gp150 expression at levels similar to those occurring in EBV-producing B cells,
we compared gp150 protein levels in Akata cells transduced with HA-gp150 or HA-gp150ΔC
lentiviruses to those in lytically induced AKBM cells. In flow cytometry using an Ab against the
Fig 6. Themechanism of gp150-induced immune evasion relies on sialoglycans shielding surface-exposed Ag-presenting molecules. A-D) CHO
and Lec2 cells expressing human β2m, HLA I, and CD1d were lentivirally transduced to co-express gp150 or HA-gp150ΔC and GFP (from EF1a and PGK
promoters, respectively). A) Lectin (WGA-FITC) binding confirmed the glycosylation defect in Lec2 cells compared to parental CHO cells. B) Migration height
of HA-gp150 was visualised byWestern blot analysis. C-D) Levels of HLA I and CD1d at the surface of HA-gp150ΔC+GFP+ (gp150+) cells were compared to
those on control, non-transduced GFP- (gp150-) cells. D) Surface levels of HLA I and CD1d are depicted as log MFI values with 95% confidence intervals, for
gp150+ versus gp150- wt CHO cells or sialylation-defective Lec2 cells. The slopes of the connecting lines (Δlog MFI) reflect the downregulation induced by
gp150. Statistical analysis was performed using two-way ANOVAs and significance of the interaction term was assessed, as described in the Material and
Methods section. One representative experiment of at least six is depicted. * p<0.01. E-L) MJS-CD1d-gp150 cells were generated by transduction with a
lentivirus encoding both gp150 and GFP (from a CMV promoter and an IRES sequence, respectively) and were analysed 3 days post-transduction by
Western blot and by flow cytometry, as for A-D with the modifications indicated below. E-H) To prevent sialylation, cells were treated with the sialic acid
transferase inhibitor (500 μM inhibitor) fluorinated P-3Fax-Neu5Ac. As a control, cells were treated with the non-fluorinated compound (500 μM, ctrl) for 4
days, starting 1 day prior to transduction. This control treatment was comparable to when cells were left untreated. E) Lectins SNAI, MALII, or PNA were used
to detect sialoglycans or desialylated glycans, respectively. G) gp150+GFPhigh cells were compared to non-transduced cells. H) One representative
experiment of two is depicted. * p<0.01. I-L) To remove surface sialylation, intact cells were treated with neuraminidase (1U/μl, 60 min, 37°C) prior to cell lysis
or lectin/Ab staining. L) One representative experiment of three is depicted. * p<0.01.
doi:10.1371/journal.ppat.1005550.g006
EBV gp150 Shields Antigen-Presenting Molecules
PLOS Pathogens | DOI:10.1371/journal.ppat.1005550 April 14, 2016 15 / 28
gp150 C-terminus, levels of gp150 in productively infected B cells appeared to exceed those in
cells transduced to express full-length gp150 in isolation (Fig 7A, left panel). The C-terminally
truncated gp150 lacks the epitope recognized by the anti-gp150 Ab. Therefore, we next com-
pared full-length and truncated gp150 expression levels in transduced B cells by means of their
HA-tag and found that levels of the cytoplasmic tailless gp150 were slightly higher than those
of the full-length protein (Fig 7A, right panel). Based on this, we reasoned that B cells express-
ing gp150ΔC in isolation likely reflect the levels occurring in the context of natural EBV-infec-
tion of B cells and we have, therefore, studied these cells in more detail.
Detection of HA-tag on non-permeabilized HA-gp150 Akata cells (Fig 7B) also shows that
the gp150 protein arrives at the surface of B cells as it did on 293T (Fig 1C) and MJS (Figs 2A,
4B and 4C, 5B and 5C) cells. At the surface of HA-gp150ΔC-transduced Akata B cells, detec-
tion of HLA I, II, CD1d, and to a lesser extent CD10 was reduced in comparison to untrans-
duced control cells (Fig 7B, upper panels). This shows that gp150 induces an immune evasive
phenotype in human B cells as it did in the other cell types studied. Neuraminidase treatment
of Akata+gp150 cells increased surface binding of Abs specific for the three Ag-presenting mol-
ecules and CD10 (Fig 7B, lower panels and bar graphs), pointing towards direct involvement of
sialic acids in gp150-induced shielding of B cell surface markers.
These data combined with those in Fig 6 of gp150 masking surface HLA I, II, and CD1d via
a glycan shield indicate that the same mechanism of action can operate both in epithelium-like
cells and in B cells, the natural targets for EBV infection in vivo.
EBV gp150 contributes to evasion of Ag presentation during productive
infection
To assess the contribution of gp150-mediated interference with Ag presentation in the full
viral context, we studied the productive phase of infection in B cells that harbour either wild-
type EBV (Akata wt) or the BDLF3 deletion mutant AkataΔgp150. Based on the use of these
cells, gp150 was earlier reported not to be essential for EBV replication in vitro, as the recombi-
nant virus had no defects in binding, infectivity, assembly, or egress [19]. In line with this, we
found no apparent differences in progression through the replicative cycle between lytically
induced Akata wt and Δgp150 cells: both expressed the EBV immediate-early BZLF1, early
BGLF5, and late gp350 proteins, but only Akata wt cells produced gp150, as did control
induced AKBM cells (S6A Fig).
To determine surface levels of the host cell molecules HLA I, II, CD1d, and CD10 by flow
cytometry, both types of induced Akata cells were counter-stained for gp350, to identify the
EBV-producing B cells. As observed for AKBM cells (Fig 1A), induction of the lytic cycle
caused a downregulation of surface display of the Ag-presenting molecules HLA I, II, and
CD1d in (gp350+) Akata wt cells, when compared to the latently infected cells (Fig 7C). In the
absence of gp150, however, HLA I, II, and CD1d surface levels were significantly higher during
productive infection, as visible when comparing gp350+ AkataΔgp150 to Akata wt cells (Fig
7C, compare tinted with non-filled grey histograms). Likewise, downregulation of the B cell
surface markers CD10 and CD86 was less pronounced in lytic cells devoid of gp150 (Fig 7C
and S6B Fig). These results indicate that gp150 contributes to the apparent downregulation of
Ag-presenting molecules and–to a lesser extent- other surface markers in a model for natural
EBV infection of human B cells.
Our combined data support a model in which surface molecules, including Ag-presenting
molecules, are shielded from recognition by the extensive glycosylation of gp150, pointing
towards a contribution of this novel EBV evasion molecule to interference with cell-mediated
immunity against EBV (Fig 8).
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Fig 7. Glycan shielding of surface Ag-presentingmolecules by gp150 occurs in human B cells and is
reversed during productive EBV infection when gp150 is deleted. A-B) Latent AkataΔgp150 cells were
lentivirally transduced to co-express either HA-gp150 or HA-gp150ΔC and GFP (from EF1a and PGK
promoters, respectively) and were puromycin-selected to obtain pure populations of gp150+ cells. B cells
already grow in suspension and gp150-positive B cells were maintained in culture for several weeks,
indicating that gp150 expression was not toxic to the cells. A) Flow cytometry was used to assess total
(intracellular staining with anti-gp150 Ab on permeabilized cells) and surface (anti-HA Ab on non-
permeabilized cells) levels of EBVgp150. Expression levels of gp150 were compared to lytically induced
AKBM cells (20 hours anti-human IgG treatment, rat CD2GFP+ cells). B) Akata+gp150 and non-transduced
control cells were left untreated or were treated with neuraminidase (1U/μl, 60 min, 37°C). Surface levels of
Ag-presenting molecules and cellular CD10 as a control were compared to gp150- non-transduced cells. One
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Discussion
Cell-mediated immunity by HLA I and II-restricted cytotoxic and helper T cells as well as by
CD1d-restricted iNKT cells is critical in the defence against many viruses [1]. Especially persis-
tent viruses, such as herpesviruses, have acquired strategies to permit their escape from elimi-
nation by these immune cells. In this study, we report that EBV infection, even in its late
productive phase, substantially reduced display of CD1d, HLA I, and HLA II complexes at the
surface of human B cells. Reduced detection of these antigen-presenting molecules was
observed with Abs that can block TCR binding. This effect is functionally important, because
HLA downregulation results in reduced T cell activation. For transmission to other target cells
or hosts, new viral particles need to be produced through EBV reactivation from latently
infected B cells, the primary natural targets for EBV infection. At the late stage of viral replica-
tion, up to 100 EBV genes are expressed, thus resulting in a wide array of Ags presented at the
surface of infected cells to T cells. EBV-specific T cells are generated upon primary infection
[6]. Therefore, immune escape strategies targeting Ag-presenting molecules including HLA I,
II, and CD1d might allow EBV-producing B cells to effectively evade T and iNKT cell surveil-
lance in vivo, prolonging the timespan for the production of viral offspring. Indeed, patients
with reduced functional T and iNKT cell numbers are known to have life-threatening compli-
cations upon encountering EBV [6].
Our finding that gp150 acts as a novel EBV-encoded immune evasion molecule causing
reduced detection of surface CD1d, HLA I, and HLA II complexes is intriguing as it is not only
the first function ascribed to this viral glycoprotein, it also reveals a novel mechanism
employed by herpesviruses to dodge immune recognition. In contrast to most herpesvirus
structural glycoproteins, EBV gp150 was found to be non-essential for viral entry, assembly, or
egress [19] and the function of this late viral protein has remained enigmatic until now. Here,
we provide evidence in support of a model in which gp150 is able to shield surface HLA
representative experiment of three is depicted. C) Viral reactivation was induced in Akata wt and Δgp150 B
cells by overnight culture with anti-human IgG and EBV-producing cells were identified by staining for the late
viral protein gp350. Surface levels of Ag-presenting molecules and CD10 on lytic (gp350+) and latent
(gp350-) cells are depicted in overlay histograms. One representative experiment of at least four is depicted.
Statistical analysis was performed for B and C) as described for Fig 6. * p<0.05, ** p<0.01.
doi:10.1371/journal.ppat.1005550.g007
Fig 8. Schematic model of a glycan shielding mechanism for T and iNKT cell immune evasionmediated by EBV gp150.
doi:10.1371/journal.ppat.1005550.g008
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molecules, through its abundantly sialylated glycans, in order to escape T cell activation (Fig
8). Cellular expression of gp150 in isolation was sufficient to reduce detection of multiple cellu-
lar surface molecules, for example interfering with binding of an Ab detecting the H-2 Kb/SIIN-
FEKL antigenic complex. Moreover, we show that B cells producing a gp150-deleted mutant
virus display more Ag-presenting molecules as compared to wild-type EBV, indicating that
gp150 contributes to immune evasion in the full viral context. EBV gp150 did not appear to
promote degradation, retention, internalization, or altered glycosylation of HLA molecules.
Rather, HLA molecules arrived at the cell surface, yet failed to be recognized, a defect which
was restored in part by preventing sialylation.
To date, only the Ebola virus glycoprotein (EBOV GP) has been described to shield host cell
surface molecules, namely HLA I and β1 integrin molecules, via its extensively glycosylated
mucin-like domain [29]. This suggests that similar mechanisms have evolved independently in
different viruses belonging to different families. Both EBOV GP’s mucin-like domain and the
ectodomain of EBV gp150 contain around 10 potential N-glycosylation and more than 70
potential O-glycosylation sites. The mucin-like domain of EBOV GP consists of mainly core 2
O-linked glycans [30]. The ‘core’ type of O-linked glycans on gp150 is, at present, unknown,
but could also consist of core 2 glycans in view of its resistance to O-glycanase that removes
core 1 and core 3 O-glycans [25]. Thus, it remains to be investigated whether the glycans of
EBV gp150 and EBOV GP share key features or whether they evolved similarly to shield host
surface molecules. Detailed characterization of the glycans of EBOV GP and EBV gp150 is
likely required to fully comprehend the molecular necessities of viral glycoproteins to shield
cell surface molecules and thereby facilitate further identification of such proteins.
It would be interesting to know whether other (herpes)viruses have incorporated similar
strategies to escape from immune recognition, as this would provide further insight into the
significance and requirements of this mechanism. The BDLF3 ORF is also present in Rhesus
LCV. Rhesus LCV BDLF3 protein displays only 46% amino acid homology to EBV gp150, but
shares the feature of the serine/threonine-rich ectodomain indicating that it too might be
heavily glycosylated. In view of the low sequence homology between the BDLF3 proteins of
these closely related γ-herpesviruses, glycosylation potential rather than amino acid sequence
might provide immune evasive properties. It will be interesting to analyse the immune evasive
properties of MHV-68 ORF28, the positional homologue of EBV BDLF3. MHV-68 ORF28 also
appears to be non-essential for viral replication in vitro and in vivo [31]. Compared to gp150,
the ectodomain of ORF28 is reduced in size, yet highly glycosylated and could therefore pro-
vide insights into the structural requirements for glycan shielding. It is tempting to speculate
that other proteins or different (herpes)viruses present functional homologues of EBV gp150
and EBOV GP that do not share amino acid similarity, yet retain the feature of a heavily glyco-
sylated extracellular domain. Intriguingly, we observed that the major envelope glycoprotein of
EBV, gp350, also interfered with surface detection of CD1d (Fig 1B) and TfR (S2B Fig).
Interestingly, not only do viruses appear to exploit a glycan shielding strategy, but also can-
cer cells show aberrant expression of sialic acid-modified glycans that are thought to play a role
in tumor immune evasion [32], which may in part be due to the reported sialylation-dependent
inhibition of NK cells by masking ligands of activating NK cell receptors [33]. Relevance of sia-
lylation-dependent immune interference by tumors is demonstrated by the fact that hypersia-
lylation of tumor cells is associated with poor prognosis for patients [34]. Interestingly, when
sialic acid decoration on tumor cells was inhibited with the same compound as we have used
(Fig 6E–6H), it resulted in reduced metastases in an in vivomouse model [35].
Our results show a direct effect of gp150 on the presentation of antigenic peptides to T cells.
In addition to Ag-presenting molecules, EBV gp150 could also affect the function of various
other cell surface molecules. Potential targets include receptor-ligand pairs involved in
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formation of the immunological synapse. An immunological synapse is formed at the interface
of the T cell and the virus-infected cell through interactions of several receptor-ligand pairs
[36]. In the centre of this synapse, HLA/Ag complexes reside, engaged by specific TCRs. Costi-
mulatory molecules locate in proximity of the Ag-presenting molecules, and are surrounded by
a ring of adhesion molecules. We have observed that cellular expression of gp150 also appears
to mask the adhesion molecule CD54/ICAM1 (Fig 2A), the costimulatory molecule CD86 (S6B
Fig), as well as TfR (S2B Fig), and CD10 (Fig 2A). Of note, shielding of these molecules appears
to require higher levels of gp150 expression than was sufficient for shielding of these Ag-pre-
senting molecules (S2C Fig, and Fig 2 & S3B Fig). In contrast, CD33, CD44, and CD55 were
not sensitive to downregulation by gp150, even when expressed at high levels (Fig 2C), showing
that gp150 does not mask all cell surface molecules. The broad target range of gp150 suggests
that other receptor-ligand interactions, such as receptor-induced apoptosis by FasL-Fas inter-
actions, or other (non)-immune cell-cell contacts could be disturbed by gp150. Intriguingly,
cell adherence and cell-cell contact were lost in floating MJS cells expressing high levels of
gp150 (S3A Fig), as was also observed for EBOV GP [29], suggesting that gp150 can uncouple,
at least partially, actively EBV-producing B cells from environmental cues. One could speculate
that the EBV-producing B cell could thus become mobile by interfering with signals that
restrain B cells at a particular site in the body, allowing them to localize for instance to tonsils,
facilitating viral shedding in saliva.
Besides the host cell molecules described above, expression of the heavily glycosylated
gp150 protein could also shield the recognition of viralmembrane-expressed proteins that
could otherwise by recognized by EBV-specific Abs. EBV exploits the endogenous glycosyla-
tion machinery of the infected cell to form glycan structures, which are, by nature, not foreign
to the immune system. When these “self-structures” are placed on a—foreign—viral protein, it
could be shielded from recognition by Ab-producing B cells. In line with this, no good Abs
against the extracellular part of gp150 are available. Furthermore, when the glycosylation is
abundant as is the case for gp150, it could also lead to the masking of other viral proteins that
are expressed at the cell/ virus surface. So far, we have not observed strongly reduced detection
of gHgL, gp350, or gB on wild-type versus gp150-null EBV-producing B cells, and it would not
be advantageous to viral entry if these receptors were fully shielded. Yet, both for EBOV GP
[37] as well as for some herpesviruses, glycosylation-mediated evasion of Ab neutralization has
been reported, for example for the proteins gN of HCMV and the bovine herpesvirus 4
(BoHV-4) gp180, which is the functional homologue of EBV gp350. Truncated HCMV gN
lacking part of its glycosylated ectodomain as well as absence of BoHV-4 gp180 renders viral
particles more sensitive to Ab neutralization [38,39]. In addition, cells infected with BoHV-4
lacking gp180 show increased Ab binding to viral proteins, pointing to the role of glycans in
shielding viral proteins from immune recognition.
Persistent viruses dedicate a large part of their genome to modulating host antiviral activi-
ties. Among these, herpesviruses have acquired a very diverse set of strategies to downregulate
Ag-presenting molecules and, thereby, T cell activation in a temporal fashion. Viral strategies
include blocking protein synthesis, depletion of antigenic peptides, dislocalization to the cyto-
plasm followed by proteasomal degradation, re-routing and/or accelerated internalization, or
steric hindrance of TCR binding [4]. In this study, we report on a novel EBV strategy: by
expressing the heavily glycosylated, late EBV protein gp150, Ag-presenting molecules on pro-
ductively infected cells are shielded from interaction with TCRs, thereby allowing replication
and production of viral particles that would otherwise by interrupted by a cellular immune
response. This mechanism is novel in herpesvirus biology, and further supports the notion that
herpesviruses use very diverse ways to achieve escape not only from T cells, but also from
iNKT cell immunity. Evasion from CD1d-mediated Ag presentation supports an essential role
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for iNKT cells in anti-EBV immunity, which was already inferred from the devastating effects
of EBV infection in XLP patients. Combining multiple strategies allows them to escape various
layers of immune elimination during various stages of infection. This underscores the notion




For T-helper cell assays, peripheral blood samples from patients and healthy individuals were
obtained after approval by the LUMC institutional review board and written informed consent
according to the Declaration of Helsinki.
Cells
All media were supplemented with 10% FCS, 100 U/ml penicillin, and 100μg/ml streptomycin.
The EBV+ BL cell lines AKBM [15], Akata wt, and Akata Δgp150 [19] were cultured in supple-
mented RPMI medium. Productive EBV infection and inhibition of late protein expression by
phosphonoacetic acid were performed as previously described [22]. Human embryonic kidney
(HEK) 293T, HEK 293H-2Kb, and the human melanoma cell line MelJuSo (MJS, HLA typing
A01, B08, DR3) and MJS-derived cell lines were cultured in supplemented DMEMmedium.
MJS-A2-GFP cells were obtained from Dr. E Reits [24]. Chinese hamster ovary (CHO) and
Lec2 cells [40] were cultured in supplemented MEM-αmedium.
Antibodies and streptavidin conjugates
Primary antibodies used in this study were mouse α-CD1d (CD1d42, CD1d51, CD1d55, D5; a
kind gift by S. Porcelli, NY, USA), mouse α-CD1d-PE (clone CD1d42, BD Pharmingen),
mouse α-HLA-ABC (W6/32), mouse α-HLA-ABC-PE (W6/32, Serotec), mouse α-HLA-A2
(BB7.2), mouse α-HLA-DR (L243), mouse α-HLA-DR-PE (L243, BD Biosciences), mouse α-
TfR (CD71, clone M-A721, BD Pharmingen), mouse α-CD10-PE (clone Hl10a, BD Pharmin-
gen), mouse α-CD34-PE (clone 8G12, BD Biosciences), rat α-CD44-PE (clone IM7, BD Phar-
mingen), mouse α-CD54-PE (ICAM-1, clone HA58, BD Pharmingen), mouse α-CD55-PE
(clone IA10, BD Pharmingen), mouse α-BZLF1 (clone BZ.1, kindly provided by Dr. M. Rowe,
Birmingham, UK), mouse α-BGLF5 (clone 311H, kindly provided by Dr. J. Chen, Taipei, Tai-
wan), mouse α-gHgL (E1D1), rabbit α-gp150 (V8), biotinylated mouse α-gp350 (72A1), rat α-
HA-tag (3F10, Roche), rat α-EBNA1-tag (1H4, kindly provided by Dr. J. Mautner), mouse α-
myc-tag (9E10). Secondary antibodies used in flow cytometry were goat α-mouse-PE
(eBioscience), donkey α-rat-APC or–FITC (Jackson Immunoresearch), and goat α-rabbit-PE
(Jackson Immunoresearch). To detect biotinylated antibodies or lectins, streptavidin-BV421 or
streptavidin-PE (both BioLegend) were used, respectively. For Western blot analysis, an HRP-
conjugated goat α-rabbit (Southern Biotech) antibody was used. For confocal microscopy, goat
α-mouse-Atto647 (Sigma) and goat α-rat-Alexa594 (Invitrogen) antibodies were used.
Plasmids
Plasmids encoding His- and EBNA1 (aa435-445, recognized by 1H4 Ab)-tagged EBV glyco-
proteins (gM, gN, gp78, gp350, and gp150) were a generous gift from Dr J. Mautner and were
described previously [41].
In this study, different lentiviral vectors were used to create third generation replication-
deficient lentiviruses. Expression of the human CD1d or HLA-A2 gene fused to a zeocin
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resistance gene by means of the ribosomal skipping peptide P2A was driven by an EF1a pro-
moter [22]. C-terminally Flag (DYKDDDDK)-tagged BMRF2, N-terminally Flag-tagged
BDLF2, and BDLF3 EBV genes were PCR-amplified from EBV B95.8 genome. PCR products
were cloned into the lentiviral vector pLV-CMV-IRES-GFP. We generated an in-frame N-ter-
minal HA-tagged (YPYDVPDYA) gp150 full-length variant and a mutant lacking the last 26
aa (209–234) of the cytoplasmic tail (HA-gp150ΔC). The PCR products were cloned behind an
EF1a promoter into the dual promotor lentiviral vector EF1a-/pGK-GFP-T2A-puro, described
elsewhere [21], and into the lentiviral vectors pLV-CMV-IRES-GFP and pLV-CMV-IRES-
puroR. The lentiviral vector encoding eGFP-myc-HLA-A2 has been described elsewhere [21].
Codon-optimized human β2m was encoded in a variant of the abovementioned dual pro-
moter lentiviral vector containing a zeocin resistance gene and mAmetrine fluorescence gene
fused by means of the ribosomal skipping peptide T2A.
Replication-deficient retroviruses and retroviral transductions
Third generation replication-deficient SIN recombinant lentiviruses were generated by PEI
transfection of 293T cells with pCMV-VSVG, pMDLg-RRE, and pRSV-REV and a lentiviral
vector coding for the genes of interest. Target cells were transduced with lentivirus supernatant
in the presence of 4 μg/ml polybrene by spin infection (1000xg, 2h, 33°C). AKBM and Akata B
cells, MJS, and 293T cells were transduced with human CD1d and selected using zeocin (200–
500 μg/ml).
MJS cells were retrovirally transduced in the presence of 12μg/ml retronectin with the
pLZRS-HCMV pp65-IRES-trNGFR vector to generate MJS-pp65 cells. Cells were FACS sorted
for surface trNGFR expression. MJS or MJS-pp65 cells were transduced with eGFP-myc-tagged
HLA-A2 or HLA-A2 to generate MJS-GFPmycA2 and MJS-A2/pp65 cells, respectively.
To generate CHO-A2-CD1d and Lec2-A2-CD1d cells, CHO and Lec2 cells were first trans-
duced with human codon-optimized β2m and selected with zeocin (500 μg/ml). Subsequently,
cells were transduced to express HLA-A2 and human CD1d. HLA-A2+CD1d+ cells were FACS
sorted using a FACS Aria III (BD).
To study gp150 in MJS cell lines, gp150 or the variants HA-gp150 or HA-gp150ΔC were
expressed from a lentiviral pCMV-IRES-GFP or pCMV-IRES-puroR vector. The empty
pCMV-IRES-GFP vector served as a control. MJS cell lines were transduced and analysed 3 to
5 days post transduction. Floating MJS cells were harvested and analysed 3–4 days post trans-
duction. CHO and AkataΔgp150 cell lines were transduced, as indicated, with gp150, HA-
gp150, or HA-gp150ΔC, which were expressed from the dual promotor lentiviral vector
pEF1a-/pGK-GFP-T2A-puroR. CHO cells were analysed up to 10 days post transduction. Aka-
taΔgp150 cells were selected using puromycin and analysed up to 4 weeks post transduction.
Transient transfection
For transient transfections, 293T cells were seeded in 12w plates one day prior to transfection.
Cells were transfected with 1 μg plasmid DNA coding for EBV proteins using Lipofecta-
mine2000 (Invitrogen) according to the manufacturer’s protocol. Cells were analysed by flow
cytometry two days post transfection.
Flow cytometry, cell sorting, and cell viability assay
To assess cell surface levels of indicated molecules, cells were stained with antibodies of indi-
cated specificity in PBS supplemented with 0,5% BSA and 0,02% sodium azide. For intracellu-
lar stains (ICS), cells were fixed in 2% PFA and permeabilized in ICS-FACS buffer (PBS, 2%
FCS, 0,5% saponine). Subsequent staining and washing steps were performed in ICS-FACS
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buffer. All stainings were performed at 4°C. Cells were fixed prior to analysis in FACS buffer
containing 2% PFA. Samples were subjected to flow cytometry using a LSR II or Canto II (BD
Biosciences). Flow cytometry data were analysed using FlowJo (Tree star) software.
For cell sorting, cells were stained with indicated antibodies in PBS supplemented with 0,5%
BSA for 1 hour on ice. Cells were washed in supplemented PBS and subjected to sorting by
flow cytometry using an Aria III (BD Biosciences). Sorted cells were washed and prepared for
use in T cell assays or Western blot analysis.
To determine cell viability by flow cytometry, unfixed cells were incubated with 7-AAD for
5 min at RT and subjected to flow cytometry. Live cells excluded the dye, whereas dead cells
become 7-AAD positive.
Functional assays
MJS-HLA-A2/pp65 cells were transduced with two different doses of lentivirus for gp150
expression or an empty vector control. Three days post-transduction, floating and adherent
cells were harvested and adherent cells were FACS sorted for GFPhigh and GFPint cells. In 96w
U-bottom plates, triplicates of 5000 cells were incubated with equal numbers of A2/pp65-speci-
fic CD8+ T cells or DR3/MiHa-specific CD4+ T cells overnight. Culture supernatants were col-
lected to determine IFN-γ secretion by ELISA (Affymetrix) according to manufacturer’s
protocol. Standard deviation was determined over biological triplicates.
For MHC/peptide-TCR interactions, 293Kb cells were transfected with gp150 or an empty
vector control. One day post-transfection, cells were peptide-pulsed for 2h with either 1 μM
ovalbumin-derived SIINFEKL peptide or the control peptide SSIEFARL. Cells were harvested
and cell surface-stained using the 25D1.16 Ab, which is specific for Kb/SIINFEKL complexes.
Samples were subjected to flow cytometry. Mean fluorescence intensity was determined for
triplicates in each experiment. Statistical analysis was performed on three independent experi-
ments using Student’s t-test (two-tailed).
Confocal microscopy
The localization of C-terminally GFP-tagged HLA-A2 expressed in MJS cells was determined
by confocal microscopy. HA-gp150ΔC-transduced cells were harvested and cell surface stained
for HLA-A2 (BB7.2) and gp150 (anti-HA) as performed for flow cytometry. Cell suspension
was applied on a glass coverslip. Cells were analysed using a Leica TCS SP5 confocal micro-
scope. Microscopy images were adjusted in levels in a linear fashion. For quantification, around
30 single cells were analysed using a composite colour image of the three different channels.
Images of single-stained cells (BB7.2 or anti-HA) were used to define the amount of fluores-
cence leakage into the regarding other channel. Prior to image quantification of double-stained
cells, measured pixel intensity was corrected for the determined leakage. Pixel intensity was
determined for the outer 8 pixels of the selected objects. Statistical analysis was performed
using an unpaired t-test (two-tailed).
Western blot
Post-nuclear cell lysates were prepared using NP40 lysis buffer (50 mM Tris HCl (pH 7.5), 150
mMNaCl, 0.5% Igepal-CA630) containing protease inhibitors (Roche, Protease cocktail), as
described previously [15]. For treatment with glycosidases, lysates were denatured at 95°C for 5
min prior to incubation with Endo H or PNGase F (both NEB) at 37°C for 1h. Proteins were
separated by SDS-PAGE and blotted onto PVDF membranes. Membranes were blocked using
5% milk in PBS. The indicated primary antibodies were used to probe membranes overnight at
4°C in 1% milk in PBST (PBS, 0,1% Tween 20). Incubation with secondary antibody was
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performed for 2 hours at RT. Antibody-reactive bands were detected by ECL and signal was
captured by film.
Protease inhibitor treatment
Cells were cultured overnight in the presence of 25 μM chloroquine (provided by Dr. A de
Wilde) or 15 nM epoxomicin (provided by Dr. H Overkleeft) to inhibit proteolysis by endoly-
sosomal proteases or cytoplasmic proteasomes, respectively.
Inhibition of sialylation
Optimal concentration of the fluorinated P-3Fax-Neu5Ac inhibitor was determined and effec-
tiveness of treatment was monitored by binding of the biotinylated lectins SNAI (Sambucus
nigra), MALII (Maackia amurensis), and PNA (Ara chishypogaea, all purchased by EY Labora-
tories). Lectin stains were performed in carbo-free blocking solution (Vector Laboratories) as
described previously [42]. Cells were treated with 500 μM fluorinated P-3Fax-Neu5Ac inhibitor
or with the control compound P-Neu5Ac 1 day prior to lentiviral transduction. Cells were cul-
tured in presence of inhibitor for additional four days and analysed by flow cytometry.
Neuraminidase treatment
Neuraminidase treatment was performed in FACS buffer containing 1U/μl neuraminidase
(NEB), at 37°C for 45–60 min. Subsequently, cells were washed and stained in cold FACS
buffer. Neuraminidase treatment was monitored by loss of binding of the biotinylated or
FITC-conjugated lectin WGA (Triticum vulgaris). Stained cells were subjected to flow
cytometry.
Statistical analysis
Fluorescence intensity signals of each analysed cell were logarithmically transformed and 1000
cells per parameter (Figs 6 and 7B, gp150-/gp150+, Fig 7C, latent/lytic) were randomly picked.
For each parameter, two “treatments” were compared (Figs 6D, CHO vs Lec2, 6H, control vs
inhibitor, 6L and 7B, untreated vs neuraminidase, 7C, WT vs Δgp150). Whether treatment dif-
ferences vary over gp150 expression has been explored by means of evaluating a statistical
interaction between these factors in an analysis of variance model. Statistical analysis was per-
formed using two-way ANOVAs and significance of the interaction terms (ctrl/gp150un-
treated/treated) was assessed using SPSS (version 20.0.0.2). p-values< 0.05 were considered
statistically significant.
Supporting Information
S1 Fig. A) EBV+ AKBM-CD1d BL cells were treated for indicated periods with anti-human
IgG Ab to induce viral replication. EBV-producing cells were identified by induced expression
of the lytic cycle reporter rat CD2-GFP. Surface levels of the Ag-presenting molecules HLA I,
II, and CD1d were determined by flow cytometry. Histograms depict overlays to allow compar-
ison of latently (rat CD2-GFP-) and lytically (rat CD2-GFP+) infected B cells. B) 293T-CD1d
cells were transfected with expression vectors encoding late EBV glycoproteins. Glycoproteins
known to require a viral interaction partner were transfected together (BMRF2/BDLF2 and
gM/gN). EBV protein expression was deduced from coexpression of GFP (BMRF2/BDLF2) or
on the basis of a C-terminal tag (gM/gN, gB, gp350, gp150). Cell surface HLA I or TfR was
stained prior to an intracellular staining for the tagged EBV proteins. Surface levels were
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compared between non-transfected and transfected cells.
(TIF)
S2 Fig. MJS-CD1d cells were transduced with lentiviruses encoding (A) the indicated EBV
immune evasion gene products (BNLF2a, BILF1, gp42+gH+gL) or only IRES-GFP (vector)
and (B,C) gp150-IRES-GFP. Surface levels of HLA I, HLA II, and CD1d (A) as well as TfR (B)
or CD10 and CD54 (C) were determined by flow cytometry on non-permeabilized cells. Histo-
grams depict a comparison of GFP- control (non-transduced) and GFP+ EBV protein-express-
ing (transduced) cells. C) A dose range of pCMV-gp150-IRES-GFP lentivirus was used for
transduction. Total gp150 expression levels in permeabilized cells were determined by intracel-
lular staining with an Ab specific for gp150’s cytoplasmic tail.
(TIF)
S3 Fig. A) The adherent MJS cell line was transduced either with the gp150-IRES-GFP lentivi-
rus or an IRES-GFP control. Three days post transduction, both the floating and adherent frac-
tions of transduced cells were subjected to flow cytometry. The proportion of floating cells was
larger for gp150-transduced cells than for control cells and, additionally, the gp150+ floating
cells were enriched for gp150 expression (reflected by higher GFP levels compared to the
adherent cells). These observations suggested that high levels of gp150 expression induce loss
of cell adherence. To exclude that the higher gp150 levels were cytotoxic, the viability of float-
ing and adherent fractions of transduced cells from the same culture dish was determined by
incubation with the live exclusion dye 7-aminoactinomycin D (7AAD) followed by flow
cytometry analysis. As controls served the adherent fraction of untreated MJS-CD1d cells (con-
trol) and the adherent and floating fractions of cells treated with toxic concentrations of the
proteasome inhibitor epoxomicin (epox; 200 nM) for 24h. In the FSCxSSC dot plots, the live
gates are depicted for the cell populations analyzed for GFP levels (transduction efficiencies)
and 7AAD exclusion (viability). An additional gate on population 1 in the floating epoxomi-
cin-treated cells shows that the 7AAD was effective in penetrating dead cells. Among both the
adherent and the floating cells transduced with either control or gp150 lentivirus, only very few
7AAD+ (dead) cells were present, indicating that gp150 does not cause gross cytotoxicity. B)
The floating cell fraction from the experiment depicted in Fig 2A was analyzed by flow cytome-
try, as described in the legend to Fig 2A.
(TIF)
S4 Fig. Three days after lentiviral transduction, four different populations were FACS
sorted fromMJS-CD1d cells that were transduced with gp150-IRES-GFP or control
IRES-GFP viruses: GFP- (1, non-transduced) and GFP+ (2, vector) cells were isolated from
control cells and the GFP+ cells from the gp150-transduction were further separated into
gp150low (3, HLA Ihigh) cells and gp150high (4, HLA Ilow) cells on the basis of the extent
of HLA I downregulation. The sorted cell populations were lysed for analysis by immunoblot
(see Fig 4B).
(TIF)
S5 Fig. Intact MJS-CD1d-gp150 and control-IRES-GFP cells were treated with decreasing
amounts of neuraminidase (5–0,008U/ml) for 60 min at 37°C and compared to untreated
cells. Effectiveness of neuraminidase treatment was monitored by WGA-FITC binding.
CD1d surface levels were determined by flow cytometry.
(TIF)
S6 Fig. A) EBV+ AKBM, Akata wt and Δgp150 BL cells were treated with anti-human IgG to
induce the viral lytic cycle. Twenty hours later, expression of several EBV proteins—BZLF1
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(immediate-early), BGLF5 (early), and gp150 and surface gp350 (both late)—was determined
using flow cytometry. B) Akata wt and Δgp150 BL cells were treated with anti-human IgG for
20 hours. Surface expression of the cellular proteins HLA I, CD1d, and CD86 was determined
using flow cytometry as described in Fig 7C.
(TIF)
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